Gwendolyn Binder-scholl PhD

Gwendolyn Binder Scholl, PhD, has served as the Executive Vice President of Adaptimmune LLC since 2012 and formerly as Vice President of Operations since March 2011. Dr Binder Scholl heads the clinical and regulatory development efforts in the United States. Dr Binder Scholl is responsible for driving all aspects of Adaptimmune LLC including its ongoing clinical trials in cancer and its development planning and implementation. She is a biochemistry and molecular biology graduate of Wells College with a PhD in cellular and molecular medicine from Johns Hopkins University.